​

Geron (GERN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GERN Stock Forecast

Geron (GERN) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $5.89, with a high of $8.00 and a low of $4.00. This represents a 360.16% increase from the last price of $1.28.

$1 $2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $5.89 Low: $4 Last Closed Price: $1.28

GERN Stock Rating

Geron stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (77.27%), 5 Hold (22.73%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 5 17 Strong Sell Sell Hold Buy Strong Buy

GERN Price Target Upside V Benchmarks

TypeNameUpside
StockGeron360.16%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$6.00
Last Closing Price$1.28$1.28$1.28
Upside/Downside--368.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 252421-9
Sep, 252421-9
Aug, 252431-10
Jul, 25243--9
Jun, 25243--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 27, 2025Peter LawsonBarclays$4.00$1.61148.45%212.50%
Nov 05, 2024Emily BodnarH.C. Wainwright$8.00$4.2488.68%525.00%
Oct 22, 2024Kalpit PatelB.Riley Financial$5.50$3.9539.24%329.69%
Sep 09, 2024Faisal KhurshidLeerink Partners$7.00$4.2564.71%446.88%
Jun 10, 2024Corinne JenkinsGoldman Sachs$6.00$4.9521.21%368.75%
Jun 10, 2024Stephen WilleyStifel Nicolaus$7.00$4.5952.51%446.88%
Apr 30, 2024Joel BeattyRobert W. Baird$4.50$4.148.70%251.56%
Mar 15, 2024Gil BlumNeedham$5.00$3.3648.81%290.63%
Mar 15, 2024Corinne JenkinsGoldman Sachs$5.00$3.3648.81%290.63%
Jan 09, 2023Needham$4.00$2.7943.37%212.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 27, 2025BarclaysOverweightOverweighthold
Nov 05, 2024H.C. WainwrightBuyinitialise
Oct 03, 2024Goldman SachsBuyBuyhold
Aug 09, 2024B. RileyBuyBuyhold
Jun 10, 2024Goldman SachsBuyBuyhold
Jun 10, 2024WedbushBuyBuyhold
Jun 10, 2024BarclaysOverweightinitialise
Jun 07, 2024Cowen & Co.BuyBuyhold
Apr 29, 2024WedbushBuyBuyhold
Sep 12, 2023Goldman SachsNeutralBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.28$-0.37$-0.37$-0.32$-0.27----
Avg Forecast$-0.26$-0.34$-0.38$-0.34$-0.25$-0.06$0.18$0.43$0.81
High Forecast$-0.13$-0.17$-0.29$-0.32$-0.11$-0.05$0.26$0.59$1.01
Low Forecast$-0.41$-0.52$-0.64$-0.35$-0.34$-0.08$0.06$0.26$0.65
Surprise %7.69%8.82%-2.63%-5.88%8.00%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$253.00K$1.39M$596.00K$237.00K$76.50M----
Avg Forecast$243.67K$424.20K$604.33K$293.17K$90.83M$294.65M$539.51M$787.06M$1.16B
High Forecast$347.02K$604.14K$920.03K$366.46K$174.00M$343.07M$543.83M$789.67M$1.39B
Low Forecast$151.52K$263.77K$486.81K$209.41K$66.34M$245.65M$535.19M$784.45M$986.66M
Surprise %3.83%228.38%-1.38%-19.16%-15.78%----

Net Income Forecast

$-300M $-120M $60M $240M $420M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-75.61M$-120.95M$-141.03M$-184.13M$-174.57M----
Avg Forecast$-149.32M$-191.74M$-111.07M$-184.13M$-127.87M$-37.96M$97.05M$253.38M$459.76M
High Forecast$-75.91M$-97.47M$-88.85M$-147.30M$-61.16M$-29.72M$148.12M$334.71M$577.78M
Low Forecast$-231.66M$-297.47M$-133.28M$-220.95M$-194.58M$-46.21M$35.27M$149.55M$371.66M
Surprise %-49.36%-36.92%26.98%-36.53%----

GERN Forecast FAQ

Is Geron stock a buy?

Geron stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Geron is a favorable investment for most analysts.

What is Geron's price target?

Geron's price target, set by 22 Wall Street analysts, averages $5.89 over the next 12 months. The price target range spans from $4 at the low end to $8 at the high end, suggesting a potential 360.16% change from the previous closing price of $1.28.

How does Geron stock forecast compare to its benchmarks?

Geron's stock forecast shows a 360.16% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Geron over the past three months?

  • October 2025: 22.22% Strong Buy, 44.44% Buy, 22.22% Hold, 11.11% Sell, 0% Strong Sell.
  • September 2025: 22.22% Strong Buy, 44.44% Buy, 22.22% Hold, 11.11% Sell, 0% Strong Sell.
  • August 2025: 20.00% Strong Buy, 40.00% Buy, 30.00% Hold, 10.00% Sell, 0% Strong Sell.

What is Geron’s EPS forecast?

Geron's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.06, marking a -77.78% decrease from the reported $-0.27 in 2024. Estimates for the following years are $0.18 in 2026, $0.43 in 2027, and $0.81 in 2028.

What is Geron’s revenue forecast?

Geron's average annual revenue forecast for its fiscal year ending in December 2025 is $294.65M, reflecting a 285.19% increase from the reported $76.5M in 2024. The forecast for 2026 is $539.51M, followed by $787.06M for 2027, and $1.16B for 2028.

What is Geron’s net income forecast?

Geron's net income forecast for the fiscal year ending in December 2025 stands at $-37.964M, representing a -78.25% decrease from the reported $-175M in 2024. Projections indicate $97.05M in 2026, $253.38M in 2027, and $459.76M in 2028.